SecBot SecBot

SIGA drug pipeline

SIGA TECHNOLOGIES INC · 1 rated drug
$2.85
+4.0% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±16.9%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
3
3 with results posted

Upcoming catalysts

1 dated
  1. Jan 1, 2027
    TPOXX
    Phase 2 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available (oral since 2018, IV since 2022).

TPOXX tecovirimat Updated Oct 28

What to watch

The next hard catalyst is Q3 2026 earnings on November 5, 2026, which will show whether TPOXX deliveries continued and whether management has secured a new multi-year BARDA procurement contract. Without a new contract, the revenue cliff from the nearly-exhausted 19C contract is the dominant risk. The longer-term catalyst is the planned FDA submission for post-exposure prophylaxis in H1 2027, but that is over six months away and not yet a binary event.

Bull case
  • TPOXX is the only FDA-approved drug specifically indicated for smallpox, a critical biodefense asset stockpiled by the U.S. Strategic National Stockpile and over 30 countries (source: siga.com).
  • SIGA is targeting an FDA submission for post-exposure prophylaxis (PEP) in H1 2027, which could expand TPOXX's addressable market beyond treatment of active disease (source: seekingalpha.com).
  • The company has a strong patent portfolio with 26 U.S. utility patents and 101 issued foreign patents protecting TPOXX (source: stocklight.com).
Bear case
  • ~86% of the $630M BARDA 19C contract has already been exercised, leaving a thin revenue backlog and a looming revenue cliff (source: panabee.com).
  • Q2 2026 revenue fell 49% YoY to $41M and EPS dropped to $0.17 from $0.49; Q1 2026 revenue was just $6.2M, showing extreme quarter-to-quarter volatility (source: tradingkey.com).
  • Two major mpox trials (PALM 007 and STOMP) failed to meet primary endpoints, and the EMA recommended withdrawing the mpox indication for tecovirimat in March 2026, removing a key growth thesis (source: bioworld.com).

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
May 18, 2022TPOXXApproval+18.8%+20.9%
Jul 13, 2018TPOXXApproval+15.1%+14.7%

Clinical trials

5 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
TPOXXStudy to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSPhase 2Active not recruiting100Jan 1, 2027
Tecovirimat Oral CapsuleStudy of Tecovirimat for Human Mpox VirusPhase 3Terminated · results719Oct 23, 2024
TPOXXSafety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysPhase 3Completed · results467May 12, 2023
TPOXXA Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatPhase 3Completed · results449Aug 24, 2016
TPOXXSafety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246Phase 2Completed · results107Jan 2010